Puma Biotechnology Inc (NASDAQ:PBYI) CEO Alan H. Auerbach sold 477 shares of the stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $32.38, for a total value of $15,445.26. Following the completion of the sale, the chief executive officer now owns 4,203,218 shares in the company, valued at approximately $136,100,198.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
PBYI stock opened at $31.94 on Tuesday. The company has a debt-to-equity ratio of 4.43, a quick ratio of 2.99 and a current ratio of 3.02. Puma Biotechnology Inc has a twelve month low of $17.60 and a twelve month high of $65.95. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -10.68 and a beta of 0.57.
Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.12. The firm had revenue of $71.10 million for the quarter, compared to analyst estimates of $53.46 million. Puma Biotechnology had a negative return on equity of 258.02% and a negative net margin of 45.22%. Sell-side analysts predict that Puma Biotechnology Inc will post -2.02 earnings per share for the current fiscal year.
A number of analysts have weighed in on PBYI shares. Leerink Swann started coverage on Puma Biotechnology in a research note on Thursday, January 17th. They issued a “market perform” rating and a $21.00 target price on the stock. Citigroup increased their target price on Puma Biotechnology from $67.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. JPMorgan Chase & Co. reiterated a “sell” rating on shares of Puma Biotechnology in a research note on Monday, April 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $57.00 target price on shares of Puma Biotechnology in a research note on Thursday, February 28th. Finally, BidaskClub upgraded Puma Biotechnology from a “strong sell” rating to a “sell” rating in a research note on Friday, January 25th. Five research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $51.91.
Institutional investors have recently made changes to their positions in the company. NumerixS Investment Technologies Inc increased its stake in shares of Puma Biotechnology by 969.5% during the fourth quarter. NumerixS Investment Technologies Inc now owns 2,139 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 1,939 shares during the period. Amundi Pioneer Asset Management Inc. purchased a new position in shares of Puma Biotechnology during the fourth quarter valued at $61,000. SG Americas Securities LLC purchased a new position in shares of Puma Biotechnology during the first quarter valued at $210,000. Quantamental Technologies LLC purchased a new position in shares of Puma Biotechnology during the fourth quarter valued at $112,000. Finally, Stephens Inc. AR purchased a new position in shares of Puma Biotechnology during the first quarter valued at $240,000. Hedge funds and other institutional investors own 92.67% of the company’s stock.
WARNING: This story was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2019/05/07/insider-selling-puma-biotechnology-inc-pbyi-ceo-sells-477-shares-of-stock.html.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous).
Featured Article: Momentum Indicator: Relative Strength Index
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.